Skip Navigation
 
 
 
 xxx
 
Print This Page
Share this page: More
 

GLIADEL® Wafers

What is the GLIADEL® wafer?

GLIADEL® wafer

The GLIADEL® wafer is a biodegradable polymer loaded with the chemotherapeutic agent BCNU used for the treatment of recurrent gliomas. It was approved by the FDA in 1995.

After surgical removal of the brain tumor, GLIADEL® wafers are soaked with a chemotherapy drug (BCNU) and are implanted in the space where the tumor was. The wafers destroy the remaining tumor cells.

This is a local drug delivery technique that eliminates the side effects of systemic chemotherapy. Standard chemotherapy affects cancer cells and healthy cells and can cause side effects like fatigue and hair loss.

 

#1 in Neurology and Neurosurgery in the U.S. for Four Consecutive Years

US News and World Report Best HospitalsThe Johns Hopkins Hospital ranked #1 in the nation in 2013 and is the only hospital in history to be ranked #1 for 21 years in a row by U.S. News & World Report.

 
 

Scheduled for Neurosurgery at Johns Hopkins?

Watch the patient experience video before you come

 

Out-of-State and International Patients - Find Out More

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer